Delcath Systems, Inc. — FY2013 Form 10-K Summary
Business Context and Reporting Period
Delcath is an oncology specialty pharmaceutical and medical device company developing the Melphalan HDS/CHEMOSAT system for regional chemotherapy treatment of primary and metastatic liver cancers. The filing covers the fiscal year ended December 31, 2013, including fourth-quarter results. CHEMOSAT had CE Mark authorization for European commercialization, while the Melphalan HDS combination product was not approved for sale in the United States.
The company remained primarily a development-stage and early commercialization business, with commercial activity focused on Germany and the United Kingdom and clinical development directed toward hepatocellular carcinoma.
Financial Performance and Key Metrics
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Total revenue | $0.8 million | $0.3 million | +$0.4 million |
| Product revenue | $0.5 million | $0.3 million | Increase |
| Other revenue | $0.3 million | — | Recognition of previously deferred revenue |
| Gross profit | $0.3 million | $0.3 million | Broadly stable |
| Gross margin | Approximately 41% | Approximately 89% | Declined |
| Operating loss | $33.0 million | $53.9 million | Improved by $20.9 million |
| Net loss | $30.3 million | $51.9 million | Improved by $21.5 million |
| Basic loss per share | $0.30 | $0.85 | Improved |
| Cash used in operating activities | $34.1 million | $50.0 million | Improved by $15.9 million |
| Cash and cash equivalents | $31.2 million | $23.7 million | +$7.5 million |
Cost of goods sold was $0.5 million, including approximately $0.3 million related to expired, obsolete or slow-moving inventory. Selling, general and administrative expense declined to $20.7 million from $28.0 million, while research and development expense declined to $12.7 million from $26.2 million. The reductions reflected lower NDA-related costs, restructuring and workforce reductions.
Fourth-quarter 2013 operating loss was $5.5 million and net loss was $4.8 million, or $0.04 per basic and diluted share. The filing’s quarterly financial table does not provide a clear fourth-quarter revenue value.
At December 31, 2013, total assets were $37.1 million, current liabilities were $6.6 million, total stockholders’ equity was $30.1 million and the accumulated deficit was $229.1 million. The company had no outstanding borrowings under its $20 million Silicon Valley Bank revolving facility. Warrant liabilities were $2.3 million. Contractual operating lease obligations totaled approximately $8.6 million, and a letter of credit of approximately $0.9 million was required under the New York office lease.
Material Changes Versus Prior Comparable Period
- Revenue increased but remained immaterial relative to operating expenses and consisted primarily of early European product sales and $0.3 million of recognized deferred revenue.
- Operating expenses decreased by approximately 38.5%, driven by lower regulatory and clinical costs and substantial workforce reductions.
- The workforce declined from 92 employees at December 31, 2012 to 37 employees at December 31, 2013. Restructuring and severance costs were approximately $4.0 million, with $2.0 million accrued at year-end.
- Cash increased despite operating cash consumption because the company raised approximately $41.7 million from stock sales and exercises of options and warrants.
- Common shares issued increased to approximately 134.3 million at year-end from 76.8 million, creating substantial dilution. The company also had approximately 14.9 million warrants outstanding at year-end.
- The FDA issued a complete response letter in September 2013 for the Melblez Kit NDA, preventing approval in its then-current form.
- Management changed following the termination of the former chief executive officer in September 2013; Jennifer Simpson and Graham Miao became interim co-presidents and co-chief executive officers.
Guidance, Outlook, Risks and Unusual Items
Management expected continuing losses in 2014 and stated that existing capital resources were sufficient to fund operations through the first half of 2015. Additional financing was expected to be required to continue operations, fund the HCC clinical program and support commercialization. Potential funding sources included equity or debt financing and strategic alliances.
Following the FDA complete response letter, the company stated that additional well-controlled randomized trial work using overall survival as the primary efficacy endpoint would be required, together with use of the product intended for marketing. Delcath planned to incorporate these requirements into its HCC clinical development program and intended to begin a global Phase 2 HCC program, subject to FDA and institutional review board actions.
The product’s clinical risk profile was a central regulatory concern. The company reported early-trial risks including treatment-related deaths, stroke, myocardial infarction, severe bone marrow suppression, febrile neutropenia, hepatic injury, hemorrhage and gastrointestinal perforation. The ODAC voted 16–0 that the benefits did not outweigh the risks associated with the early clinical versions of the system.
European commercialization remained dependent on reimbursement and physician adoption. Germany’s Value 4 reimbursement status permitted hospitals to negotiate coverage but did not mandate reimbursement. United Kingdom funding initiatives and NICE review outcomes were uncertain. Reimbursement was inadequate or unresolved in several other European markets.
Material risks included continued operating losses and negative cash flow, dependence on additional financing, regulatory failure, limited commercial experience, reimbursement uncertainty, sole-source or limited-source suppliers, availability of melphalan, manufacturing and quality requirements, product liability, clinical-trial execution, competition, patent expiration and potential dilution. The company also disclosed securities class-action and derivative litigation relating to alleged disclosures concerning the NDA and manufacturing facilities.
NASDAQ had notified the company that its stock price failed the $1.00 minimum bid requirement. Stockholders subsequently approved authority for a potential reverse stock split between 1-for-8 and 1-for-16, although the board had not determined whether or when to implement it.
Important Facts for Investors to Verify
- Whether Delcath obtained sufficient financing after the filing to fund operations beyond the first half of 2015.
- The status, design, enrollment and cost of additional FDA-required randomized trials and the HCC clinical program.
- Whether the FDA complete response letter was resolved and whether U.S. approval was ultimately obtained.
- European procedure volume, pricing, gross margins and actual reimbursement, particularly in Germany and the United Kingdom.
- The company’s ability to generate recurring product revenue relative to its cash burn and fixed lease obligations.
- Current common shares outstanding, warrant exercises, future equity issuance and dilution risk.
- The outcome and potential financial exposure from the securities and derivative shareholder litigation.
- Whether the reverse stock split occurred and whether NASDAQ listing compliance was maintained.